{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:04:16Z","timestamp":1787508256024,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T00:00:00Z","timestamp":1470873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T00:00:00Z","timestamp":1470873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Primary breast sarcoma (PBS) is a rare and heterogeneous group of malignancies with limited publications. We obtained data from the Surveillance, Epidemiology, and End Results Program and performed analysis to determine clinicopathological characteristics of PBS and estimate their associations with overall survival (OS) and cancer-specific survival (CSS). Median age of PBS was 55\u201359 years and median OS was 108 months. Age, overlap or entire breast involvement, tumor histology, and tumor spread were associated with poor survival outcomes. In the multivariable analysis, tumor size, lymph node involvement, distant metastasis and histologic grade were correlated with survival outcomes (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). In M0 patients, mastectomy was associated with worse survival outcomes compared with breast conservative surgery (BCS) (adjusted hazard ratio [adjHR], 1.80; 95% CI, 1.31\u20132.47), regardless of tumor size, tumor grade, tumor histology or radiation history. Adjuvant radiation improved survival outcomes in patients with tumor size &gt;5\u2009cm (adjHR, 0.63; 95% CI, 0.43\u20130.91), but not in patients with tumor size\u2009\u2264\u20095\u2009cm. Our study demonstrated clinicopathological characteristics of PBS in the US population and supports performing BCS if R0 resection can be achieved, with radiation if tumor size is over 5\u2009cm.\n                  <\/jats:p>","DOI":"10.1038\/srep31497","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T05:16:16Z","timestamp":1470892576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Primary female breast sarcoma: clinicopathological features, treatment and prognosis"],"prefix":"10.1038","volume":"6","author":[{"given":"Ming","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heath B.","family":"Mackley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Drabick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold A.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,11]]},"reference":[{"key":"BFsrep31497_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00006534-199101000-00045","volume":"87","author":"DS May","year":"1991","unstructured":"May, D. S. & Stroup, N. E. The incidence of sarcomas of the breast among women in the United States, 1973\u20131986. Plastic and reconstructive surgery 87, 193\u2013194 (1991).","journal-title":"Plastic and reconstructive surgery"},{"key":"BFsrep31497_CR2","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/cncr.21531","volume":"104","author":"SA Vorburger","year":"2005","unstructured":"Vorburger, S. A. et al. Angiosarcoma of the breast. Cancer 104, 2682\u20132688, 10.1002\/cncr.21531 (2005).","journal-title":"Cancer"},{"key":"BFsrep31497_CR3","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/JCO.2003.06.080","volume":"21","author":"L Zelek","year":"2003","unstructured":"Zelek, L. et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 21, 2583\u20132588, 10.1200\/JCO.2003.06.080 (2003).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep31497_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF01806549","volume":"13","author":"P Terrier","year":"1989","unstructured":"Terrier, P. et al. Primary breast sarcoma: a review of 33 cases with immunohistochemistry and prognostic factors. Breast cancer research and treatment 13, 39\u201348 (1989).","journal-title":"Breast cancer research and treatment"},{"key":"BFsrep31497_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/sj.bjc.6601920","volume":"91","author":"C Adem","year":"2004","unstructured":"Adem, C., Reynolds, C., Ingle, J. N. & Nascimento, A. G. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. British journal of cancer 91, 237\u2013241, 10.1038\/sj.bjc.6601920 (2004).","journal-title":"British journal of cancer"},{"key":"BFsrep31497_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0360-3016(99)00444-7","volume":"46","author":"TS McGowan","year":"2000","unstructured":"McGowan, T. S. et al. An analysis of 78 breast sarcoma patients without distant metastases at presentation. International journal of radiation oncology, biology, physics 46, 383\u2013390 (2000).","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"BFsrep31497_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1586\/era.12.82","volume":"12","author":"G Lahat","year":"2012","unstructured":"Lahat, G. et al. Sarcomas of the breast. Expert review of anticancer therapy 12, 1045\u20131051, 10.1586\/era.12.82 (2012).","journal-title":"Expert review of anticancer therapy"},{"key":"BFsrep31497_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1200\/JCO.2003.12.047","volume":"21","author":"DK Gaffney","year":"2003","unstructured":"Gaffney, D. K., Tsodikov, A. & Wiggins, C. L. Diminished survival in patients with inner versus outer quadrant breast cancers. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 21, 467\u2013472 (2003).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep31497_CR9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1200\/JCO.2002.20.3.791","volume":"20","author":"MW Kattan","year":"2002","unstructured":"Kattan, M. W., Leung, D. H. & Brennan, M. F. Postoperative nomogram for 12-year sarcoma-specific death. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 20, 791\u2013796 (2002).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep31497_CR10","doi-asserted-by":"crossref","unstructured":"Group, E. S. E. S. N. W. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology\/ESMO 25 Suppl 3, iii102\u2013112, 10.1093\/annonc\/mdu254 (2014).","DOI":"10.1093\/annonc\/mdu254"},{"key":"BFsrep31497_CR11","unstructured":"Network, N. C. C. Soft Tissue Sarcoma (Version 2.2016). http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf. Accessed March 19, 2016."},{"key":"BFsrep31497_CR12","first-page":"505","volume":"116","author":"H Gutman","year":"1994","unstructured":"Gutman, H. et al. Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery 116, 505\u2013509 (1994).","journal-title":"Surgery"},{"key":"BFsrep31497_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0002-9610(03)00269-1","volume":"186","author":"DK Blanchard","year":"2003","unstructured":"Blanchard, D. K., Reynolds, C. A., Grant, C. S. & Donohue, J. H. Primary nonphylloides breast sarcomas. American journal of surgery 186, 359\u2013361 (2003).","journal-title":"American journal of surgery"},{"key":"BFsrep31497_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1200\/JCO.1998.16.1.197","volume":"16","author":"JC Yang","year":"1998","unstructured":"Yang, J. C. et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 16, 197\u2013203 (1998).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep31497_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijrobp.2009.04.051","volume":"77","author":"M Koshy","year":"2010","unstructured":"Koshy, M., Rich, S. E. & Mohiuddin, M. M. Improved survival with radiation therapy in high-grade soft tissue sarcomas of the extremities: a SEER analysis. International journal of radiation oncology, biology, physics 77, 203\u2013209, 10.1016\/j.ijrobp.2009.04.051 (2010).","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"BFsrep31497_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jamasurg.2013.3049","volume":"149","author":"S Agarwal","year":"2014","unstructured":"Agarwal, S., Pappas, L., Neumayer, L., Kokeny, K. & Agarwal, J. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA surgery 149, 267\u2013274, 10.1001\/jamasurg.2013.3049 (2014).","journal-title":"JAMA surgery"},{"key":"BFsrep31497_CR17","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1002\/cncr.22228","volume":"107","author":"OK Macdonald","year":"2006","unstructured":"Macdonald, O. K., Lee, C. M., Tward, J. D., Chappel, C. D. & Gaffney, D. K. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer 107, 2127\u20132133, 10.1002\/cncr.22228 (2006).","journal-title":"Cancer"},{"key":"BFsrep31497_CR18","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/cncr.27795","volume":"119","author":"ES Hwang","year":"2013","unstructured":"Hwang, E. S., Lichtensztajn, D. Y., Gomez, S. L., Fowble, B. & Clarke, C. A. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer 119, 1402\u20131411, 10.1002\/cncr.27795 (2013).","journal-title":"Cancer"},{"key":"BFsrep31497_CR19","doi-asserted-by":"crossref","unstructured":"Maaren, M. C., Munck, L., Bock, G. H. et al. Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: A population-based study with 37,207 patients. AACR Proceedings, Abstract S3\u201305 (2015).","DOI":"10.1158\/1538-7445.SABCS15-S3-05"},{"key":"BFsrep31497_CR20","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1002\/cncr.28181","volume":"119","author":"ES Hwang","year":"2013","unstructured":"Hwang, E. S., Clarke, C. A. & Gomez, S. L. Reply to survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer 119, 3254\u20133255, 10.1002\/cncr.28181 (2013).","journal-title":"Cancer"},{"key":"BFsrep31497_CR21","unstructured":"RJ, L. An introduction to classification and regression tree (CART) analysis. Available at:http:\/\/citeseerx.ist.psu.edu\/viewdoc\/download?doi=10.1.1.95.4103&rep=rep1&type=pdf Accessed March 19, 2016."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep31497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep31497","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep31497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:12:10Z","timestamp":1672877530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep31497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,11]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,8,30]]}},"alternative-id":["BFsrep31497"],"URL":"https:\/\/doi.org\/10.1038\/srep31497","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,11]]},"assertion":[{"value":"26 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Joseph J. Drabick is a consultant for Merck. Harold A. Harvey is a consultant for Genentech. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31497"}}